Saudi Arabia Cell and Gene Therapy Market Size To Worth USD 1,026.3 Million By 2034 | CAGR of 17.82%

Saudi Arabia Cell and Gene Therapy Market Overview

Market Size in 2025: USD 234.5 Million

Market Size in 2034: USD 1,026.3 Million

Market Growth Rate 2026-2034: 17.82%

According to IMARC Group's latest research publication, "Saudi Arabia Cell and Gene Therapy Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", The Saudi Arabia cell and gene therapy market size was valued at USD 234.5 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,026.3 Million by 2034, exhibiting a CAGR of 17.82% during 2026-2034.

How AI is Reshaping the Future of Saudi Arabia Cell and Gene Therapy Market

● AI-Powered Patient Screening and Genetic Analysis: Artificial intelligence is revolutionizing cell and gene therapy development across Saudi Arabia by enabling advanced genomic sequencing and patient stratification capabilities that identify suitable candidates for personalized treatments, with machine learning algorithms analyzing complex genetic data from populations characterized by high rates of consanguinity-related inherited disorders including sickle cell disease, beta thalassemia, and rare metabolic conditions, thereby accelerating clinical trial recruitment and improving treatment outcomes through precise patient selection and targeted therapeutic interventions.

● Automated Manufacturing Process Optimization: Advanced AI systems are transforming cell and gene therapy production facilities in Saudi Arabia by streamlining manufacturing workflows through predictive analytics and real-time quality control monitoring, enabling hospitals and biotechnology centers to optimize CAR T-cell production, stem cell processing, and viral vector manufacturing with enhanced efficiency and reduced contamination risks, while machine learning models predict optimal culture conditions and identify potential quality issues before they impact therapeutic efficacy, supporting the Kingdom's goal of producing up to 100 gene therapies annually.

● Personalized Treatment Design and Dosage Optimization: Machine learning algorithms are enhancing personalized medicine capabilities in Saudi cell and gene therapy programs by analyzing patient-specific factors including disease progression patterns, genetic profiles, immune system characteristics, and treatment response data to design customized therapeutic approaches, optimize dosage regimens for CAR T-cell and stem cell therapies, and predict potential adverse events, enabling clinicians to deliver more effective treatments while minimizing risks and improving patient safety across oncology, genetic disorder, and rare disease applications.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-cell-gene-therapy-market/requestsample

Saudi Arabia Cell and Gene Therapy Market Trends & Drivers:

Saudi Arabia's cell and gene therapy market is experiencing transformative growth driven by the government's strategic focus on localizing advanced therapeutic manufacturing capabilities and reducing dependence on imported treatments through Vision 2030 initiatives. The Kingdom's ambitious National Biotechnology Strategy aims to establish Saudi Arabia as a global hub for life sciences innovation by 2040, with significant investments in state-of-the-art manufacturing facilities capable of producing CAR T-cell therapies, stem cell treatments, and viral vector technologies domestically. King Faisal Specialist Hospital & Research Centre's groundbreaking manufacturing facility, spanning over 5,000 square meters with 16 modular clean-room clusters, represents a milestone achievement enabling local production of up to 100 gene therapies annually and projected to achieve cost savings of SAR 8 billion by 2030 while meeting approximately 9% of national demand for advanced therapies through domestic manufacturing capabilities.

The Kingdom's unique demographic and genetic landscape creates unprecedented demand for cell and gene therapies, with higher rates of consanguinity leading to increased prevalence of inherited disorders including sickle cell disease, beta thalassemia, Fanconi anemia, and rare metabolic conditions that require advanced therapeutic interventions. The Saudi Food and Drug Authority has demonstrated strong regulatory support by approving 10 groundbreaking clinical trials since 2020, including therapies for spinal muscular atrophy, sickle cell disease, and hemophilia B, while establishing streamlined approval pathways through the Breakthrough Medicines Program that positioned Casgevy as the first CRISPR-based therapy approved in the Kingdom. The SFDA's commitment to accelerating innovation through integrated electronic systems for clinical trial submissions and partnerships with the Saudi National Institute of Health has resulted in a 40% increase in clinical trials during 2024, creating a robust ecosystem for research and development activities.

International collaborations and strategic partnerships are accelerating market expansion, with major pharmaceutical companies and biotechnology firms establishing significant presence in Saudi Arabia through technology transfer agreements, joint research initiatives, and local manufacturing commitments. The Kingdom's biotech market is projected to grow at 14% CAGR reaching approximately USD 12 billion by 2030, supported by government incentives, research funding programs through the Research, Development and Innovation Authority, and infrastructure investments in biotech clusters designed for regional and global export capabilities.

Saudi Arabia Cell and Gene Therapy Industry Segmentation:

The report has segmented the market into the following categories:

Therapy Type Insights:

● Cell Therapy
● Stem Cell
● Pluripotent Stem Cell
● Cancer Stem Cell
● Adult Stem Cell
● Non-Stem Cell
● T Cells
● Natural Killer
● Others
● Gene Therapy

Indication Insights:

● Cardiovascular Disease
● Oncology Disorder
● Genetic Disorder
● Infectious Disease
● Neurological Disorder
● Others

Delivery Mode Insights:

● In-Vivo
● Ex-Vivo

End User Insights:

● Hospitals
● Cancer Care Centers
● Pharmaceutical & Biotechnology Companies
● Others

Breakup by Region:

● Northern and Central Region
● Western Region
● Eastern Region
● Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Ask analyst of customized report: https://www.imarcgroup.com/request?type=report&id=32739&flag=E

Recent News and Developments in Saudi Arabia Cell and Gene Therapy Market

● January 2025: Charles River partnered with Lafana Holding to launch the Saudi Cell and Gene Therapy Accelerator Program, supporting biotech ecosystem growth by offering comprehensive CDMO services, investment aid, and scientific advisory support to advance Saudi Arabia's capabilities and improve patient access in the gene therapy sector.

● May 2025: King Faisal Specialist Hospital & Research Centre and Cellenkos signed a strategic memorandum of understanding to launch the first clinical trial alliance between the Kingdom of Saudi Arabia and the United States, underscoring commitment to advancing medical innovation and strengthening strategic global collaborations in cell and gene therapy development.

● October 2025: King Faisal Specialist Hospital & Research Centre launched Saudi Arabia's first facility for manufacturing genetic and cellular therapies, designed to provide thousands of patients with access to advanced treatments locally while reducing healthcare costs and meeting national demand for CAR T-cell and stem-cell therapies through domestic production capabilities.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302

This release was published on openPR.